
Browsing restrictions can be lifted for a fee.
0.55%
Camp4 therapeutics corporation
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Camp4 therapeutics corporation (CAMP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CAMP's short-term business performance and financial health. For the latest updates on CAMP's earnings releases, visit this page regularly.
According to the latest financial report, Camp4 therapeutics corporation (CAMP) reported an Operating Profit of -13.65M with an Operating Margin of -1,717.11% this period, representing a growth of 2.73% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Camp4 therapeutics corporation (CAMP) announced revenue of 795K, with a Year-Over-Year growth rate of 21.93%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Camp4 therapeutics corporation (CAMP) had total debt of 6.35M, with a debt ratio of 0.07. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Camp4 therapeutics corporation (CAMP) held Total Cash and Cash Equivalents of 76.88M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Camp4 therapeutics corporation (CAMP) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,717.11%%, and net margin of -1,899.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CAMP's profit trajectory and future growth potential.
According to the past four quarterly reports, Camp4 therapeutics corporation (CAMP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Camp4 therapeutics corporation (CAMP)'s Free Cash Flow (FCF) for the period is -11.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 15.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.